[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xuanwu Hospital, Beijing\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":645},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,179,0,25,[9,41,67,96,117,154,184,206,226,247,273,298,329,349,372,396,423,446,470,494,516,546,571,600,621],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100595379","effects-and-mechanisms-of-temporal-interference-brain-stimulation-on-memory-function-in-preclinical-alzheimers-disease-100595379",false,"NCT07031687","Effects and Mechanisms of Temporal Interference Brain Stimulation on Memory Function in Preclinical Alzheimer's Disease","Inclusion Criteria:\n\n* Individuals recruited from neurology memory clinics or communities.\n* Age between 60 and 80 years old, inclusive; no gender limitation.\n* Right-handed.\n* Cognitive function test results within normal range after age, gender, and education-level adjustment, OR mild cognitive impairment not yet meeting diagnostic criteria for Mild Cognitive Impairment (MCI), OR only subjective cognitive decline.\n* Individuals classified as preclinical AD based on the revised 2024 AD diagnostic and staging criteria (i.e., cognitively normal with positive plasma p-tau217 or positive Aβ PET).\n* Full understanding of the study, voluntary participation, and provision of written informed consent approved by the Ethics Committee.\n\nExclusion Criteria:\n\n* Past or present neurological diseases (e.g., stroke, epilepsy, Parkinson's disease, multiple sclerosis).\n* Psychiatric disorders such as severe depression or severe anxiety.\n* Systemic diseases causing cognitive decline (e.g., severe thyroid dysfunction, severe liver or kidney disease, severe nutritional deficiencies).\n* Currently taking medications that may affect cognitive function (e.g., anticholinergics, benzodiazepines, antipsychotics) that cannot be discontinued or adjusted.\n* Other factors leading to cognitive decline that are not AD-related.\n* Contraindications for MRI scans, such as claustrophobia, implanted metallic devices (e.g., pacemakers, cochlear implants, aneurysm clips), or history of head injury with retained metal fragments.","ALL","60 Years","80 Years",{"count":20,"type":21},1200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if personalized, multimodal imaging-guided, EEG-based closed-loop Temporal Interference Brain Stimulation (TIBS) can improve memory function in individuals with preclinical Alzheimer's Disease (AD).\n\nThe main questions it aims to answer are:\n\n1. Does personalized TIBS lead to significant changes in functional connectivity strength of hippocampal-cortical networks at the end of the 2-week intervention compared to baseline?\n2. What are the short-term (end of 2-week intervention) and medium-to-long-term (4 weeks and 12 weeks post-intervention) effects of personalized TIBS on episodic and working memory, as well as other cognitive domains in preclinical AD?\n3. How does personalized TIBS modulate brain activity and connectivity, as measured by EEG power spectra and functional MRI (fMRI) functional connectivity, in preclinical AD?\n4. What is the safety profile of personalized TIBS in this population?\n\nResearchers will compare participants receiving active personalized TIBS to participants receiving sham (inactive) stimulation to see if TIBS effectively improves memory function and induces neural plasticity.\n\nParticipants will:\n\n1. Undergo initial screening including neuropsychological assessments and blood p-tau217 testing to identify preclinical AD.\n2. Receive either active personalized TIBS or sham stimulation daily for 40 minutes, 6 days a week, for 2 weeks.\n3. Have individualized TIBS parameters (e.g., target localization, intensity) determined using baseline structural MRI and DTI.\n4. Undergo real-time high-density EEG monitoring during daily stimulation sessions to enable closed-loop adjustment of stimulation parameters.\n5. Participate in follow-up assessments at the end of the 2-week intervention, and at 4 weeks and 12 weeks post-intervention.\n6. Receive multimodal imaging (sMRI, rs-fMRI, task-fMRI, DTI) and blood biomarker assessments at various time points.\n7. Receive Aβ-PET and tau-PET scans, along with comprehensive neuropsychological assessments, at the 12-week follow-up.\n8. Have their safety continuously monitored throughout the study.",[27],"Alzheimer Disease","RECRUITING","2026-08-20",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":32},"2025-07-01",{"date":36,"type":21},"2029-12-31",{"name":38,"class":39},"Xuanwu Hospital, Beijing","OTHER",2,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":66,"locationsCount":4},"100652962","ai-driven-health-management-to-prevent-ischemic-stroke-in-high-risk-adults-100652962","NCT07779668","AI-Driven Health Management to Prevent Ischemic Stroke in High-Risk Adults","Intelligent Early Warning of Ischemic Cerebrovascular Disease Based on Multi-Source Data Fusion and Demonstration of Tiered Prevention and Control in Beijing","AI-ExpoStroke","Inclusion Criteria:\n\n* Age 30 years or older, with no restriction on sex. Permanent resident of Beijing. No previously diagnosed stroke based on prospective community screening. Identified as being at high risk of stroke by the AI-ExpoStroke model in combination with the established stroke \"8+2\" high-risk factors.\n\nAble to comply with study follow-up and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Previous diagnosis of ischemic stroke or hemorrhagic stroke. Severe cognitive impairment. Severe organic disease, including malignant tumors, heart failure of NYHA class III or higher, renal failure, or other severe conditions.\n\nPsychiatric or language impairment that prevents completion of study questionnaires or follow-up.\n\nInability to obtain complete follow-up data or unwillingness to permit access to relevant study data.","30 Years",{"count":51,"type":21},26000,[24],"This study will evaluate whether an artificial intelligence (AI)-driven dynamic health management strategy can help prevent ischemic stroke in adults at high risk of stroke. Participants will be identified through community-based screening in Beijing using the AI-ExpoStroke model together with established stroke risk factors.\n\nCommunities will be randomly assigned to either an AI-driven health management group or a usual community-based health management group. Participants in the AI-driven group will receive continuous health management supported by a digital platform, mobile applications or WeChat-based tools, wearable-device data when available, personalized health guidance, and remote support from community health care providers. Participants in the usual-care group will receive routine community health services, including health examinations, health education, chronic disease follow-up, and medication guidance.\n\nParticipants will be followed for 36 months. The main goal is to determine whether AI-driven health management reduces the occurrence of first-ever ischemic stroke. The study will also evaluate transient ischemic attacks, stroke-related disability, mortality, control of major vascular risk factors, adherence to health management, and health economic outcomes.",[55],"Ischemic Stroke",[57,58,59],"Artificial Intelligence","Stroke Prevention","Primary Prevention","NOT_YET_RECRUITING","2026-08-18",{"date":31,"type":32},{"date":64,"type":21},"2026-08-31",{"date":36,"type":21},{"name":38,"class":39},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":40},"100612407","phase-3-tenecteplase-before-interhospital-transfer-for-evt-in-acute-anterior-circulation-lvo-at-45-24-hours-100612407","NCT07253181","Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours","Tenecteplase Before inteRhospital Transfer for Endovascular Treatment in pAtientS With acUte Anterior ciRculation Large vEssel Occlusion at 4.5 to 24 Hours","TREASURE","Inclusion Criteria:\n\n* Age of 18 years or older;\n* AIS symptom onset to treatment initiation within 4.5 to 24 hours, stroke onset is defined as the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke);\n* Signs and symptoms consistent with the diagnosis of an acute anterior circulation ischemic stroke involving occlusion of the internal carotid artery (ICA), M1 or proximal M2 vessels;\n* Functionally independent (mRS 0-2) prior to stroke onset;\n* Baseline National Institute of Health Stroke Scale (NIHSS) of 6-25;\n* Intended to transfer to ECCs for EVT (patient transfer), or intended to transfer a neurointerventionalist from the ECC for EVT (physician transfer);\n* Written informed consent from patients or legally authorized representatives;\n* Neuroimaging: large vessel occlusion (ICA, M1, proximal M2) by MRA or CTA AND the target mismatch profile on computed tomography perfusion (CTP) or magnetic resonance perfusion (MRP), defined as an ischemic core volume \\\u003C70mL, mismatch volume ≥15mL and mismatch ratio ≥1.8;\n\nAlternative neuroimaging (if CTP or MRP is technically inadequate or unavailable):\n\nAn Alberta Stroke Program Early CT Score (ASPECTS) score ≥7 on NCCT or MRI scan;\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to any ingredients of Tenecteplase;\n* Intended to receive IVT as standard-of-care therapy;\n* Rapidly improving symptoms with NIHSS score \\\u003C6 before randomization;\n* Any contra-indication for IVT except for the time criterion;\n* Known hereditary or acquired hemorrhagic diathesis;\n* Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, INR \\>1.7 or prothrombin time \\>15s; if use of any direct oral anticoagulant within the last 48 hours; if on any full dose heparin\u002Fheparinoid within the last 24 hours;\n* Ischemic stroke or myocardial infarction in previous 3 months\n* Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months;\n* Severe, uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg);\n* Other serious, advanced or terminal illness with life expectancy less than 6 months;\n* Baseline blood glucose \\\u003C50mg\u002Fdl or \\>400mg\u002Fdl;\n* Contraindication to imaging with contrast agents;\n* Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA or MRA (e.g. bilateral MCA occlusions, or an MCA and a basilar artery occlusion);\n* Extensive early ischemic change on non-contrast CT or MRI-DWI estimated to be \\>1\u002F3 MCA territory, or significant hypodensity outside the Tmax\\>6s perfusion lesion that invalidates mismatch criteria (if patient is enrolled based on CT perfusion criteria); any CT or MRI findings indicative of a high risk of sICH related to potential intravenous tenecteplase treatment in the judgement of the investigator;\n* Evidence of intracranial tumor (mass effect), acute intracranial hemorrhage, or arteriovenous malformation;\n* Current participation in another investigational drug or device study;\n* Suspected endocarditis;\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;","18 Years",{"count":77,"type":21},572,[79],"PHASE3","This study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who present in the 4.5- to 24-hour time window before interhospital transfer to an endovascular capable center (ECC) for endovascular treatment (EVT).\n\n* Primary objective: To evaluate the efficacy and safety of Tenecteplase administration at a nECC before EVT transfer compared with standard of care\n* Secondary objective: To evaluate the impact of time from needle-to-arterial puncture on clinical outcomes Patients who meet inclusion criteria will be randomized to Tenecteplase (0.25mg\u002Fkg, maximum 25mg) before transfer or standard of care. A single bolus dose should be injected over 5 seconds.",[82,83,84],"Acute Ischemic Stroke","Large Vessel Occlusion","Transportation of Patients",[86,87,88],"interhospital transfer","acute ischemic stroke","anterior circulation large vessel occlusion",{"date":90,"type":32},"2026-08-19",{"date":92,"type":32},"2026-01-06",{"date":94,"type":21},"2028-03-30",{"name":38,"class":39},{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100595202","effects-of-transcranial-electrical-stimulation-on-cognitive-impairment-in-cns-inflammatory-demyelinating-diseases-100595202","NCT07029386","Effects of Transcranial Electrical Stimulation on Cognitive Impairment in CNS Inflammatory Demyelinating Diseases","The Effectiveness of Individualized Transcranial Electrical Stimulation in Improving Cognitive Impairment in Patients With Central Nervous System Inflammatory Demyelinating Diseases","Inclusion Criteria:、\n\n1. Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis (MS), and other Central Nervous System Inflammatory Demyelinating Diseases that meet diagnostic criteria;\n2. Patients with SDMT scores \\\u003C55 or subjective cognitive decline;\n3. Age between 18 and 65 years, gender unrestricted;\n4. Hamilton Anxiety and Depression Scale scores \\\u003C7 points for both scales;\n5. No relapse or medication changes in the past month;\n6. EDSS (Expanded Disability Status Scale) score ≤6;\n7. Right-handed, native Chinese speakers with sufficient educational background to understand the test instructions;\n8. Willing to participate and have signed informed consent.-\n\nExclusion Criteria:\n\n1. Relapse record within the past month;\n2. Medication adjustment within the past month or having undergone modified electroconvulsive therapy, transcranial magnetic stimulation, or other neuromodulation techniques;\n3. Participating in any other clinical research within 1 month prior to enrollment or currently;\n4. Presence of cochlear hearing aids, cardiac pacemakers, or implanted brain stimulation devices;\n5. Skin integrity damage at electrode placement sites, or allergy to electrode gel or adhesives;\n6. History of epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infections;\n7. Pregnant or lactating women, or those planning pregnancy in the near future;\n8. Scoring ≥3 on item 3 (suicide item) of the HDRS-17 or concurrent severe mental illness;\n9. Concurrent severe or unstable organic diseases;\n10. Unable to cooperate with treatment, follow-up, or clinical, EEG, and imaging data collection due to poor patient compliance;\n11. Other situations deemed inappropriate for study participation by the researchers.","65 Years",{"count":105,"type":21},40,[24],"Background: Central nervous system inflammatory demyelinating diseases often lead to significant cognitive impairment, presenting a critical challenge in patient management.\n\nObjective: To evaluate the effectiveness of individualized transcranial electrical stimulation (tES) in improving cognitive function among patients with inflammatory demyelinating disorders.\n\nMethods: This study will assess cognitive performance through standardized neuropsychological assessments before and after individualized tES intervention, measuring changes in cognitive domains including memory, attention, executive function, and processing speed.\n\nAnticipated Results: the investigators hypothesize that personalized transcranial electrical stimulation will demonstrate significant improvements in cognitive performance, potentially offering a non-invasive therapeutic approach for managing cognitive decline in central nervous system inflammatory demyelinating diseases.\n\nSignificance: This research may provide novel insights into neuromodulation strategies for cognitive rehabilitation in patients with complex neurological conditions.",[109],"Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System",{"date":90,"type":32},{"date":112,"type":32},"2024-12-15",{"date":114,"type":21},"2027-10-01",{"name":38,"class":39},1,{"id":118,"slug":119,"hasResults":12,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100607371","trial-of-early-minimally-invasive-catheter-evacuation-with-thrombolysis-in-intracerebral-hemorrhage-100607371","NCT07187687","TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage","TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage (TIME-ICH): A Prospective, Multi-center, Open-label, Adaptive, Randomized Controlled Trial","TIME-ICH","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Pre-randomization head CT demonstrating an acute, spontaneous, primary ICH;\n3. ICH volume ≥ 20mL as calculated by the ABC\u002F2 method;\n4. The randomization can be completed within 8 hours after the onset of stroke symptoms (or the time last known to be well), and study intervention can reasonably be initiated within 4 hours after randomization.\n5. Historical Modified Rankin Score 0 or 1;\n6. Obtain informed consent from patient or legal representative.\n\nExclusion Criteria:\n\n1. Infratentorial intraparenchymal hemorrhage including midbrain, pontine, or cerebellar;\n2. Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct, tumor stroke, recurrence of a recent (\\\u003C1 year) ICH, as diagnosed with radiographic imaging;\n3. Presence of spot sign in CT angiography;\n4. Blood pressure control before randomization is ineffective, systolic blood pressure \\> 220 mmHg;\n5. Irreversible impaired brain stem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS ≤ 4;\n6. Hemorrhage with apparent midbrain extension with third nerve palsy or dilated and non-reactive pupils. Other (supranuclear) gaze abnormalities are not exclusions;\n7. Intraventricular extension of the Hemorrhage is visually estimated to involve \\>50% of either of the lateral ventricles;\n8. Any irreversible coagulopathy or known clotting disorder.\n9. Platelet count \\\u003C 750,000, INR \\> 1.4 after correction\n10. Patients requiring long-term anti-coagulation that needs to be initiated \\\u003C 30 days from index ICH;\n11. Use of 2 or more antithrombotic drugs prior to symptom onset;\n12. Patients with a mechanical heart valve;\n13. Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or is post-menopausal;\n14. Urokinase allergy;\n15. Any concurrent serious illness that would interfere with the outcome assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease;\n16. Inability or unwillingness of patient or legal representative to give written informed consent;\n17. Known life-expectancy of less than 6 months;\n18. Participation in a concurrent interventional medical investigation or clinical trial.",{"count":126,"type":21},750,[24],"TIME-ICH (TrIal of early Minimally Invasive catheter Evacuation with thrombolysis in IntraCerebral Hemorrhage) is a multicenter, randomized, adaptive clinical trial comparing best medical management to early minimally invasive surgery with thrombolysis (eMIST) in the treatment of acute spontaneous supratentorial intracerebral hemorrhage.",[130],"Intracerebral Hemorrhage",[130,132,133,134,135,136,137,138,139,140,141,142,143,144],"Intracranial Hemorrhages","ICH","brain hemorrhage","Hemorrhage","Cerebrovascular Disorders","Brain Diseases","Minimally invasive catheter evacuation","Minimally invasive surgery","Neurosurgery","Thrombolysis","Urokinase","Medical Economic","Hospital Economics","2026-08-10",{"date":147,"type":32},"2026-08-11",{"date":149,"type":32},"2025-10-24",{"date":151,"type":21},"2028-03-01",{"name":38,"class":39},63,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":161,"targetDuration":163,"studyType":164,"phases":4,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":116},"100650568","intelligent-microcatheter-shaping-for-intracranial-aneurysm-coil-embolization-100650568","NCT07749404","Intelligent Microcatheter Shaping for Intracranial Aneurysm Coil Embolization","Safety and Effectiveness of Intelligent Microcatheter Shaping Simulation Technology in Coil Embolization of Intracranial Aneurysms: A Prospective, Multicenter, Observational, Real-World Registry Study","Inclusion Criteria:\n\n1. Age 18 years or older, with no restriction based on sex.\n2. Diagnosis of an intracranial aneurysm confirmed by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography, with the target aneurysm planned for treatment by coil embolization.\n3. Ability to understand the study requirements and treatment procedures and provision of written informed consent before any study-specific procedure.\n\nExclusion Criteria:\n\n1. Currently unable or expected to be unable to complete the 1-year follow-up.\n2. Participation in another clinical study that may affect the results of this study.\n3. Life expectancy of less than 1 year because of another disease or medical condition.\n4. Considered unsuitable for participation by the investigator.",{"count":162,"type":21},1438,"12 Months","OBSERVATIONAL","This prospective, multicenter, observational registry study will evaluate the real-world safety, effectiveness, and clinical value of artificial intelligence (AI)-assisted microcatheter shaping during coil embolization of intracranial aneurysms.\n\nAdults with an intracranial aneurysm who are scheduled to undergo coil embolization will be enrolled and followed for approximately 12 months. The study will not assign participants to a treatment strategy. All treatment decisions will be made by the treating physicians according to routine clinical practice.\n\nParticipants will be analyzed according to whether microcatheter shaping is performed based on the physician's experience alone or with assistance from an intelligent microcatheter shaping simulation technology. The study will evaluate major adverse events within 12 months, immediate aneurysm occlusion after the procedure, clinical and quality-of-life outcomes, follow-up imaging findings, serious adverse events, repeat treatment or rehospitalization, microcatheter delivery performance, and health care resource use. At least 1,438 participants are planned to be enrolled.",[167],"Intracranial Aneurysm",[57,169,170,171,172,167,173,174,175],"Computer-Assisted Microcatheter Shaping","Microcatheter Shaping","Coil Embolization","Endovascular Treatment","Real-World Registry","Medical Device","Neurointervention","2026-08-02",{"date":178,"type":32},"2026-08-06",{"date":180,"type":21},"2026-08-01",{"date":182,"type":21},"2029-12",{"name":38,"class":39},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":16,"minAge":192,"maxAge":18,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":116},"100542551","application-of-tdcs-stimulation-in-controlling-refractory-status-epilepticus-100542551","NCT06344338","Application of tDCS Stimulation in Controlling Refractory Status Epilepticus","Application of Targeting Transcranial Direct Current Stimulation (tDCS) Stimulation in the Treatment of Refractory Status Epilepticus","tDCS","Inclusion Criteria:\n\n* Age between 14 and 80 year-old with Gender unlimited,\n* Suitable for EEG monitoring;\n* Clinical diagnosis of Refractory status epilepticus (status epilepticus that cannot be controlled by two types of antiepileptic drugs and at least one anesthetic);\n* Informed consent to participate in this study was obtained from the participants or their surrogates\n\nExclusion Criteria:\n\n* Unstable vital signs (systolic blood pressure\\\u003C90mmHg, heart rate\\\u003C60 beats\u002Fmin, pulse oxygen saturation\\\u003C90%);\n* Having severe skull injury\u002Fdefect or medical equipment implanted in the head;\n* Pregnancy;\n* With any implantable electronic instrument (including pacemakers, vagus nerve stimulators) or metal implanted devices.","14 Years",{"count":194,"type":21},32,[24],"The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus",[198],"Refractory Status Epilepticus",{"date":200,"type":32},"2026-08-04",{"date":202,"type":32},"2024-04-01",{"date":204,"type":21},"2026-10-01",{"name":38,"class":39},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":212,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":116},"100649947","study-on-the-incremental-predictive-value-of-early-resting-state-eeg-phenotypes-for-functional-prognosis-and-risk-stratification-in-acute-ischemic-stroke-100649947","NCT07741669","Study on the Incremental Predictive Value of Early Resting-State EEG Phenotypes for Functional Prognosis and Risk Stratification in Acute Ischemic Stroke","Inclusion Criteria:\n\n* Age \\>=18 years, regardless of sex;\n* Meets diagnostic criteria for acute ischemic stroke, supported by cranial CT\u002FMRI and\u002For vascular imaging;\n* Symptom onset time or last-known-well time is clear;\n* Clinical assessment indicates that resting-state EEG can be completed without delaying acute treatment;\n* Pre-stroke mRS \\\u003C=2, or basic independence in daily living before stroke;\n* The patient, legal guardian, or impartial witness provides informed consent to participate in this study.\n* The primary analysis population will be restricted to patients with mild-to-moderate to moderately severe acute ischemic stroke; an NIHSS score of 4-18 is recommended.\n\nExclusion Criteria:\n\n* Primary diagnosis of hemorrhagic stroke, cerebral venous sinus thrombosis, brain tumor, encephalitis, severe traumatic brain injury, or other non-ischemic brain injury;\n* Pre-existing marked neurological disability, pre-stroke mRS \\>2, severe prior dementia, or severe psychiatric disorder that would make follow-up functional or cognitive outcomes difficult to interpret;\n* Persistent deep sedation, coma, mechanical ventilation, severe metabolic disturbance, severe infection, or other conditions at the time of EEG acquisition that the investigator judges would markedly affect resting-state EEG background activity;\n* Status epilepticus or recent frequent clinical seizures around the time of EEG acquisition that the investigator judges would substantially affect interpretation of resting-state EEG;\n* Any other condition that the investigator judges unsuitable for participation in this study.",true,{"count":214,"type":21},5,"This is a single-center, prospective, observational cohort study that plans to consecutively enroll 400 patients with acute ischemic stroke from July 2026 to July 2029. The study will not interfere with acute-phase treatment decisions; information on reperfusion and non-reperfusion treatment will be recorded according to the actual clinical care pathway. After completion of necessary acute treatment, once vital signs are stable and clinical conditions permit, all participants will undergo one resting-state EEG recording as early as possible, within 7 days after symptom onset or the last-known-well time. For patients receiving reperfusion therapy, EEG will be acquired after completion of the reperfusion procedure, and intervals such as onset-to-reperfusion initiation and completion of reperfusion-to-EEG acquisition will be recorded. For patients not receiving reperfusion therapy, EEG will be acquired after the stroke diagnosis is established, routine treatment has been initiated, and the clinical condition is stable; onset-to-admission and onset-to-EEG acquisition intervals will be recorded. EEG features will be extracted and combined with clinical and imaging variables to construct prognostic models. The primary outcome is functional outcome at 3 months after onset, dichotomized as mRS 0-2 versus 3-6. The primary analysis will evaluate the incremental predictive value of EEG phenotypes for poor 3-month functional outcome beyond a conventional clinical-imaging model. Secondary analyses will include validation of 6-month outcomes, functional and cognitive scale outcomes, and differences in EEG phenotypes across treatment pathways.",[217],"Stroke","2026-07-28",{"date":220,"type":32},"2026-08-03",{"date":222,"type":21},"2026-07-15",{"date":224,"type":21},"2029-07-28",{"name":38,"class":39},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":116},"100619521","basilar-artery-occlusion-chinese-endovascular-registry-in-patients-with-large-core-infarct-100619521","NCT07345702","Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct","Endovascular Versus Medical Therapy for Acute Large-Core Basilar Artery Occlusion: A Multicenter Retrospective Registry Study (BAOCHE-LC)","BAOCHE-LC","Inclusion Criteria:\n\n1. Age ≥18 years, men or women.\n2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA\u002FMRA\u002FDSA.\n3. Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.\n4. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.\n\nExclusion Criteria:\n\n1. Subjects with occlusions in both anterior and posterior circulation.\n2. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).\n3. Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset\u002Flast known well time, or missing major treatment information including whether EVT was performed).\n4. Baseline NIHSS score \\\u003C6.\n5. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.\n6. Missing follow-up outcomes at 90 days.\n7. Any other condition judged by investigators to substantially affect analysis or interpretation.",{"count":235,"type":21},518,"This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.",[238,55,239],"Basilar Artery Occlusion","Large Core Infarct",{"date":241,"type":32},"2026-07-30",{"date":243,"type":32},"2026-01-31",{"date":245,"type":21},"2026-10-31",{"name":38,"class":39},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":18,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},"100649463","guided-laminectomy-with-augmented-duroplasty-for-acute-traumatic-spinal-cord-injury-100649463","NCT07733401","Guided Laminectomy With Augmented Duroplasty for Acute Traumatic Spinal Cord Injury","Efficacy and Safety of Bony Decompression Combined With Dural Decompression Versus Isolated Bony Decompression for Acute Severe Traumatic Spinal Cord Injury: A Prospective, Multicenter, Randomized Controlled Trial","GLAD","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old, with no restrictions on gender;\n2. Patients diagnosed with traumatic cervical or thoracic spinal cord injury (C2-T12) via clinical evaluation including medical history collection, physical examination and auxiliary imaging tests;\n3. Classified as Grade A, B or C according to the ASIA Impairment Scale (AIS) based on the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI);\n4. Scheduled to receive surgical intervention within 72 hours after traumatic spinal cord injury;\n5. Preoperative T2-weighted MRI shows no cerebrospinal fluid signal between the spinal cord and dura mater at a minimum of one vertebral segment;\n6. Good general physical condition with an expected survival time of no less than 12 months;\n7. Voluntarily participate in this trial, sign the written informed consent form, exhibit good compliance and cooperate with all follow-up visits;\n8. Judged by attending surgeons to meet the surgical indications for posterior laminectomy and spinal internal fixation, with surgical decision-making based on surgeons' clinical experience.\n\nExclusion Criteria:\n\n1. Transverse spinal cord injury;\n2. Gunshot or penetrating sharp spinal cord injury;\n3. Pre-existing dural laceration caused by traumatic spinal cord injury;\n4. Spinal cord injury without radiographic abnormality (SCIWORA, spinal injury without fracture or dislocation);\n5. Acute exacerbation of pre-existing chronic spinal cord injury;\n6. Traumatic spinal cord injury complicated with epidural or subdural hematoma;\n7. Severe concomitant traumatic brain injury defined as a Glasgow Coma Scale (GCS) score \\\u003C 14; patients unable to follow simple verbal commands due to altered mental status; or patients with clinically significant abnormalities on cranial CT (only patients with suspected brain injury identified by investigators require cranial CT scanning);\n8. Presence of underlying comorbidities that contraindicate surgery or interfere with accurate medical and neurological assessments (judged by the principal investigator).",{"count":256,"type":21},80,[24],"The goal of this clinical trial is to learn whether expansile duraplasty can improve neurological recovery in adult patients with acute severe traumatic spinal cord injury, as well as evaluate the safety of this surgical strategy. The main questions the study aims to answer are:\n\n1. Does expansile duraplasty lead to superior motor function recovery in patients with acute severe traumatic spinal cord injury?\n2. How safe is the use of expansile duraplasty in people with acute traumatic SCI?\n\nResearchers will compare neurological function, quality of life and all safety indicators who receive expansile duraplasty to that of participants who do not receive expansile duraplasty, to determine whether the additional expansile duraplasty provides better recovery benefits for patients with traumatic spinal cord injury.\n\nParticipants will be randomly assigned to one of two groups: the laminectomy combined with expansile duraplasty group and the laminectomy-only group. All participants will complete the following procedures:\n\n1. Receive standardized spinal surgery ;\n2. Provide blood and cerebrospinal fluid samples during hospitalization;\n3. Undergo spinal computed tomography (CT) and magnetic resonance imaging (MRI) scans at baseline (pre-operation), discharge, 3 months, 6 months and 12 months after surgery;\n4. Complete standardized neurological assessments at 3, 6 and 12 months postoperatively, including ASIA motor and sensory scores, Walking Index for Spinal Cord Injury II (WISCI II), and Spinal Cord Independence Measure III (SCIM III);\n5. Fill out questionnaires at each follow-up visit, including the 36-Item Short Form Health Survey (SF-36);\n6. Be continuously monitored for all adverse events and surgical complications throughout the 12-month follow-up period.",[260,261],"Spinal Cord Injury","Acute Spinal Cord Injury (SCI)",[263],"Acute Spinal Cord Injury","2026-07-24",{"date":266,"type":32},"2026-07-29",{"date":268,"type":21},"2026-09",{"date":270,"type":21},"2029-09",{"name":38,"class":39},13,{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":295,"leadSponsor":297,"locationsCount":116},"100649420","phase-4-evaluating-the-efficacy-and-safety-of-daridorexant-transition-from-bzras-in-insomnia-patientseasy-tip-100649420","NCT07733414","Evaluating the Efficacy and Safety of Daridorexant Transition From BZRAs in Insomnia Patients（EASY-TIP）","EASY-TIP","Inclusion Criteria:\n\n1. Male or female, aged ≥18 and ≤70 years.\n2. Meet DSM-5 diagnostic criteria for insomnia disorder: dissatisfaction with nighttime sleep despite adequate sleep opportunity, manifested as difficulty initiating sleep, difficulty maintaining sleep (frequent awakenings or difficulty returning to sleep after awakening), or early-morning awakening with inability to resume sleep, accompanied by subjective experience of daytime dysfunction. Symptoms occur ≥3 times per week and persist for ≥3 months.\n3. Received stable BZRA monotherapy for at least 3 nights per week during the 1 month prior to enrollment.\n4. Bedtime duration of no less than 7 hours per night.\n5. Unsatisfactory response or intolerance to current therapy, with clinical need to adjust insomnia medication regimen.\n6. Hamilton Anxiety Rating Scale (HAMA-14) score \\\u003C14.\n7. Hamilton Depression Rating Scale (HAMD-17) score \\\u003C17.\n8. Willing and able to comply with the study protocol and provide written informed consent.\n\nExclusion Criteria:\n\n1. History of chronic insomnia \\>5 years.\n2. Other sleep disorders such as narcolepsy-related symptoms, restless legs syndrome, circadian rhythm sleep disorder, REM sleep behavior disorder, etc.\n3. Daytime napping ≥1 hour\u002Fday and ≥3 days\u002Fweek.\n4. Daily BZRA dose exceeding the maximum recommended dose for insomnia treatment per package insert.\n5. BZRA use \\>5 nights per week.\n6. History of BZRA treatment ≥3 years.\n7. Concurrent use of two or more BZRAs within the past 3 months.\n8. Use of central nervous system depressants within the past 3 months.\n9. Use of long-acting sedative-hypnotics (e.g., clonazepam) within the past 3 months.\n10. Use of anxiolytics or antidepressants for off-label insomnia treatment within the past 3 months.\n11. Initiation of cognitive behavioral therapy for insomnia (CBT-I) within 1 month prior to Visit 1.\n12. Prior non-response to orexin receptor antagonists (daridorexant, lemborexant, suvorexant, etc.).\n13. Clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal) that may affect participant safety or interfere with study assessments, as judged by the investigator. Participants for whom sedative medications are contraindicated due to occupational or safety reasons are also excluded.\n14. Severe psychiatric disorder within the past 6 months, or severe alcohol\u002Fsubstance abuse\u002Fdependence within the past 2 years.\n15. Active suicidal ideation or behavior within the past 6 months.\n16. Pregnancy, lactation, or planned pregnancy within 90 days.\n17. Unable to avoid excessive alcohol consumption during the study.\n18. History of hypersensitivity to any component of daridorexant tablets.\n19. Severe hepatic impairment (Child-Pugh score ≥10).\n20. Unable to discontinue strong CYP3A4 inhibitors and strong or moderate CYP3A4 inducers during the study.","70 Years",{"count":282,"type":21},156,[284],"PHASE4","Brief Summary:\n\nThis study is a prospective, multicenter, open-label cohort study designed to evaluate the efficacy and safety of transitioning adult patients with insomnia from benzodiazepine receptor agonists (BZRAs) to daridorexant.\n\nA total of 156 participants will be enrolled. The study consists of a 1-week baseline phase and a 9-week daridorexant treatment phase. During the treatment phase, daridorexant 50 mg is initiated once daily while BZRAs are gradually tapered and discontinued based on individual patient response.\n\nThe primary outcome is the proportion of patients who successfully transition from BZRAs to daridorexant at Week 5, defined as a ≥50% reduction or complete discontinuation of the original BZRA dose, with continued willingness to take daridorexant and no withdrawal due to worsening insomnia or adverse events. Secondary outcomes include changes in Insomnia Severity Index (ISI) scores and patient-reported sleep outcomes.\n\nThis study aims to provide real-world evidence for the safe and effective transition from BZRAs to daridorexant in clinical practice.",[287],"Insomnia Disorders",[289,290,291,292],"Insomnia Disorder","Daridorexant","BZRAs","Drug Transition",{"date":266,"type":32},{"date":180,"type":21},{"date":296,"type":21},"2030-12-01",{"name":38,"class":39},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":16,"minAge":306,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":317,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":328},"100623395","pre-operative-risk-assessment-combined-with-targeted-intervention-in-the-chinese-elderly-with-spine-surgery-ii-100623395","NCT07396077","Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II","Multimodal Physiological Reserve Optimizing Prehabilitation Program (PHYSIO-Prehab) in the Chinese Elderly With Spine Surgery","PRACTICE-2","Inclusion Criteria:\n\n1. Aged ≥75 years at the time of screening\n2. Voluntarily sign the informed consent form\n3. Clinically diagnosed with degenerative lumbar spinal disorders with duration of symptoms \\>6 months\n4. Requiring elective lumbar fusion surgery (single-level or multi-level, open or minimally invasive approach)\n5. No severe cognitive impairment (Mini-Mental State Examination score \\> 9)\n6. Scheduled to undergo surgery within 6-8 weeks after screening (allowing completion of the 6-week prehabilitation program)\n\nExclusion Criteria:\n\n1. Scheduled to undergo other emergency surgery or day surgery\n2. Urgent medical conditions requiring priority management before spinal surgery\n3. With spinal disorders other than degenerative diseases (spinal fracture, tumor, metastasis, infection, ankylosing spondylitis, scoliosis with Cobb angle \\>40°)\n4. With contraindications to prehabilitation exercise (New York Heart Association Class IV heart failure, unstable angina, uncontrolled hypertension \\[systolic BP ≥180 mmHg or diastolic BP ≥110 mmHg despite medication\\])\n5. With severe functional disability for other disorders or long-term bedridden status unable to perform basic physical activities\n6. With allergy or intolerance to nutritional supplements used in the prehabilitation program\n7. Participating in another clinical trial involving prehabilitation, perioperative intervention, or spinal surgery within 3 months before screening","75 Years",{"count":308,"type":21},248,[24],"This multicenter, parallel-group, assessor-blinded randomized controlled trial will enroll 248 adults aged ≥75 years with degenerative lumbar spinal diseases scheduled for elective lumbar fusion surgery, and they will be randomized 1:1 into the intervention and usual care groups. The intervention group will receive a 6-week PHYSIO-Prehab multimodal prehabilitation program, including multicomponent exercise, nutritional intervention, comorbidity optimization, and cognitive prehabilitation with brain protection strategies. The control group will receive standard health education provided via a manual, and both groups will receive consistent perioperative Enhanced Recovery After Surgery care. The primary outcome will be the change in Barthel Index (a tool for assessing independence in activities of daily living) from baseline to 30 days postoperatively; secondary outcomes will include pain scores, disability, patient satisfaction, and the 30-day postoperative Comprehensive Complication Index. The trial will initiate recruitment in April 2026 and conclude in December 2027, aiming to evaluate the feasibility and efficacy of PHYSIO-Prehab and provide high-quality evidence for patient-centered perioperative care pathways in this population.",[312,313,314,315,316],"Spine Degeneration","Lumbar Degenerative Disease","Frail Elderly","Enhanced Recovery After Surgery (ERAS) Protocol","Prehabilitation",[316,318,319,320],"ERAS","lumbar fusion","ADL",{"date":322,"type":32},"2026-07-27",{"date":324,"type":32},"2026-04-15",{"date":326,"type":21},"2027-12-30",{"name":38,"class":39},4,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":16,"minAge":103,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":346,"leadSponsor":348,"locationsCount":328},"100647888","the-impact-of-multimodal-brain-monitoring-on-postoperative-outcomes-in-elderly-patients-undergoing-major-abdominal-surgery-100647888","NCT07713355","The Impact of Multimodal Brain Monitoring on Postoperative Outcomes in Elderly Patients Undergoing Major Abdominal Surgery","Impact of Multimodal Brain Monitoring Under General Anesthesia on Postoperative Outcomes in Elderly Patients Undergoing Major Abdominal Surgery: A Multicenter, Prospective, Single-blind, Randomized Controlled Study","Inclusion Criteria:\n\nAged ≥65 years, regardless of gender; Scheduled for elective abdominal surgery with general anesthesia duration (from anesthesia induction to surgery completion) ≥ 2 hours; American Society of Anesthesiologists (ASA) physical status classification of I-III; Body mass index (BMI) of 18.5-29.9 kg\u002Fm²; Postoperative hospital stay expected to exceed 72 hours; Compliant with ethical standards, with voluntary signed informed consent.\n\nExclusion Criteria:\n\nSevere cardiovascular diseases, including:\n\nHistory of myocardial infarction within the past 6 months; Bradycardia (resting heart rate \\\u003C50 beats\u002Fmin); Uncontrolled hypertension (sitting systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg during screening); Sitting systolic blood pressure ≤90 mmHg during screening; History of severe valvular heart disease; Uncontrolled severe respiratory infections: e.g., severe pneumonia, acute bronchitis.\n\nAbnormal liver function: Aspartate Aminotransferase (AST) and\u002For Alanine Aminotransferase (ALT) ≥2.5×Upper Limit of Normal (ULN), Total Bilirubin (TBIL) ≥1.5×Upper Limit of Normal (ULN); Abnormal renal function: urea or blood urea nitrogen (BUN) ≥1.5×Upper Limit of Normal (ULN), serum creatinine \\>Upper Limit of Normal (ULN); Admission hemoglobin A1c (HbA1c) ≥6.5% or ≥2 fasting blood glucose measurements ≥180 mg\u002Fdl (10 mmol\u002FL) and\u002For random blood glucose ≥200 mg\u002FdL (≈11.1 mmol\u002FL); Preoperative anemia (Hemoglobin \\[Hb\\] ≤90 g\u002FL), thrombocytopenia (Platelet \\[PLT\\] ≤80×10⁹\u002FL), hypoproteinemia (Albumin \\[Alb\\] ≤30 g\u002FL); History of drug abuse and\u002For alcoholism within the past 2 years (alcoholism defined as daily average alcohol consumption \\>2 units, where 1 unit = 360 mL beer or 45 mL 40% ethanol liquor or 150 mL wine); Neurological diseases (e.g., stroke within 6 months, Alzheimer's disease, Parkinson's disease, mental disease, myasthenia gravis) or psychiatric disorders (e.g., schizophrenia, mania, bipolar disorder, delirium), history of long-term use of neuropsychiatric medications, or cognitive impairment; Allergy or contraindication to study medications; Patients refusing or unable to cooperate with the study; Scheduled for pancreatic surgery; Other conditions deemed inappropriate for participation by the investigator.",{"count":337,"type":21},368,[24],"The purpose of this clinical trial is to investigate the effect of multimodal brain monitoring under general anesthesia on postoperative outcomes in elderly patients undergoing abdominal surgery.The research hypothesis is that multimodal brain monitoring under general anesthesia can reduce the incidence of postoperative composite complications and improve postoperative outcomes in elderly patients undergoing major abdominal surgery.\n\nEligible patients will be randomly assigned in a 1:1 ratio to the Multimodal Brain Monitoring under General Anesthesia Group (MBMGA group) and the Bispectral Index Monitoring under General Anesthesia Group (BIS group). The primary outcome is the postoperative composite complication rate . Secondary outcomes include intraoperative hyperglycemia, adverse events during anesthesia induction and maintanance, changes in blood pressure and heart rate, intraoperative hypotension, the dosage of perioperative anesthetics and vasoactive drugs, changes in serum cortisol, cardiac troponin I, blood creatinine (Cr) level, extubation time and awake time, the rate of transferring to ICU or AICU, The time to first use analgesia pump and the cumulative dose of postoperative oxycodone, systemic complications, hospitalization time, first exhaust time , first oral intake time, rate of second surgery and mortality within 30 days postoperatively.\n\nParticipants will:\n\n1. Undergo routine preoperative fasting for 6-8 hours;\n2. Prior to anesthesia induction, cooperate with the establishment of intravenous access, arterial catheterization, monitoring of physiological parameters, blood sample collection, and receive fluid preloading;\n3. During surgery, for patients in the MBMGA group , propofol and remifentanyl will be adjusted according to multimodal brain monitoring indices (WLi and PTi), while for patients in the BIS group, only propofol will be adjusted based on bispectral index and remifentanyl will be adjusted according to anesthesiologists' experience; simultaneously, vital signs, including respiration, body temperature, fluid therapy, blood pressure, and heart rate regulation, will be monitored and managed.\n4. After surgery, endotracheal tubes will be removed once extubation criteria are met, and patients will be transferred to the PACU, where they will receive routine monitoring and will be discharged from the PACU upon meeting corresponding scoring criteria;\n5. Participates in follow-ups on the day of surgery and for 1-30 days postoperatively, during which investigators will record the primary outcome and secondary outcomes.",[341,342],"Anesthesia, General","Major Abdominal Surgeries",{"date":344,"type":32},"2026-07-20",{"date":180,"type":21},{"date":347,"type":21},"2028-12-30",{"name":38,"class":39},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":103,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":116},"100647854","effects-of-transcranial-alternating-current-stimulation-on-postoperative-anxiety-in-patients-undergoing-intraspinal-tumor-resection-100647854","NCT07713368","Effects of Transcranial Alternating Current Stimulation on Postoperative Anxiety in Patients Undergoing Intraspinal Tumor Resection","Inclusion Criteria:\n\n* Age 18 to 65 years old\n* Scheduled for elective intraspinal tumor resection under general anesthesia\n* American Society of Anesthesiologists physical status I-III\n* Able to understand and complete the Hospital Anxiety and Depression Scale and other study-related questionnaires\n* Voluntarily sign the informed consent form\n* Right handed\n\nExclusion Criteria:\n\n* Preoperative HADS-A score ≥ 8\n* History of psychiatric disorders (e.g., depression, psychosis) or use of psychotropic medications within the past 3 months\n* History of neurological diseases (e.g., epilepsy, stroke, dementia) or severe head trauma\n* Contraindications to transcranial alternating current stimulation, including metallic implants in the head, skull defects, or a history of seizures\n* Severe visual or auditory impairment that affects communication\n* severe cardiovascular and cerebral vascular diseases\n* Participation in other clinical trials within the past 30 days\n* A Mini-Mental State Examination (MMSE) score \\\u003C 15",{"count":356,"type":21},102,[24],"The incidence of postoperative anxiety in surgery ranges from 4.1% to 79.6% , and among patients undergoing intraspinal tumor resection surgery, the incidence of postoperative anxiety is as high as 46.7%.Adverse effects induced by anxiety include insomnia, exacerbated pain, impaired wound healing and immune function, increased risk of adverse cardiovascular events, and postoperative cognitive dysfunction. These may lead to postoperative depression and chronic pain, significantly delaying patient recovery.\n\nThe goal of this study is to investigate the effects of intraoperative transcranial alternating current stimulation on postoperative anxiety in adult patients undergoing intraspinal tumor resection. It will also evaluate the safety of the transcranial alternating current stimulation.\n\nThis study will enroll adult patients undergoing elective intraspinal tumor resection surgery. The study will compare the transcranial alternating current stimulation with a sham stimulation to see whether the intervention can reduce the incidence of postoperative anxiety. The trial will also compare the anxiety scores, the incidence of delirium, pain scores, frial scores, sleep quality scores, recovery quality scores and adverse events between intervention and control groups. We also plan to compare the electroencephalography parameters and serum level of substance P to investigate the potential mechanism.",[360],"Postoperative Anxiety in Patients Undergoing Intraspinal Tumor Resection",[362,363,364,365],"Transcranial Alternating Current Stimulation","Postoperative Anxiety","Intraspinal Tumor Resection","Postoperative Recovery",{"date":344,"type":32},{"date":368,"type":21},"2026-07-01",{"date":370,"type":21},"2029-03-31",{"name":38,"class":39},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":16,"minAge":380,"maxAge":17,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":116},"100570507","temporal-interference-for-drug-resistant-epilepsy-100570507","NCT06708143","Temporal Interference for Drug Resistant Epilepsy","Noninvasive Temporal Interference Stimulation for the Treatment of Drug Resistant Epilepsy","TIE","Inclusion Criteria:\n\n* Participants are between the ages of 6 -60 years of age.\n* Patients must be clinically evaluated as having drug resistant epilepsy.\n* Persistence of disabling seizures at least 2 times per months or greater.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Psychogenic non-epileptic seizures within 12 months;\n* Presence of implanted electrical stimulation medical device anywhere in the body (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagal nerve stimulators are allowed if the parameter remains stable for at least 3 months prior to the screening visit;\n* Risk factors that would put the participant at risk for intraoperative or postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for chronic anticoagulation or antiplatelet aggregation medications; IQ \\\u003C 55 or severe cognitive dysfunction, unable to complete the study; Diagnosed with a progressive neurological disorder (including progressive Rasmussen's encephalitis, etc.);\n* Diagnosed with a severe neuropsychiatric disorder such as dementia, major depression (admission to a psychiatric specialty\u002Fhospital within 5 years or any suicidal or self-injurious tendencies), schizophrenia, or neurodegenerative disorders;\n* Diagnosed with other serious physical disorders, internal diseases or severe abnormalities in liver or kidney function; Pregnant, or planning to pregnant within 2 years; Participation in another clinical study within 3 months; Not suitable for enrollment as assessed by the multidisciplinary team of the center.","6 Years",{"count":382,"type":21},30,[24],"This single-center prospective study aims to investigate the treatment efficacy of temporal interference (TI) in drug-resistant epilepsy patients aged 6-60.",[386],"Drug Resistant Epilepsy",[388,386],"Temporal Interference",{"date":390,"type":32},"2026-07-17",{"date":392,"type":32},"2024-11-30",{"date":394,"type":21},"2028-11-30",{"name":38,"class":39},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":103,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":116},"100636513","preventive-analgesia-with-anrikefon-in-laparoscopic-cholecystectomy-100636513","NCT07566663","Preventive Analgesia With Anrikefon in Laparoscopic Cholecystectomy","Effect of Preventive Analgesia With Anrikefon on Postoperative Acute Pain and Rehabilitation Process in Adult Patients Undergoing Laparoscopic Cholecystectomy","ANIPAP","Inclusion Criteria:\n\n1. ASA physical status classification I-III;\n2. Age 18-65 years;\n3. Scheduled for elective laparoscopic cholecystectomy;\n4. Voluntary signed informed consent;\n5. BMI between 18-28 kg\u002Fm²;\n6. No history of general anesthesia surgery within the past 3 months.\n\nExclusion Criteria:\n\n1. Severe cardiovascular disease, respiratory disease, or psychiatric disorders;\n2. Severe renal insufficiency;\n3. Recent use of diuretics or compound medications containing diuretics;\n4. Continuous use of opioid analgesics for more than 10 days within the past 3 months;\n5. Use of medications with unknown half-life affecting analgesic efficacy within 14 days prior to randomization;\n6. Pregnant women, lactating women, or those planning pregnancy in the near future;\n7. History of hypersensitivity to study medications.",{"count":405,"type":21},274,[24],"This study will determine the optimal timing for Anrikefon administration. It will also assess the quality of patient recovery. Laparoscopic cholecystectomy (LC) is a routine surgical procedure. However, the incidence of acute visceral and incision pain is high, reaching 50% to 70%. This pain significantly impairs patient recovery.\n\nAnrikefon is novel peripherally restricted κ-opioid receptor agonist. It has very low brain penetration. This property reduces central nervous system side effects and respiratory depression. Preventive analgesia blocks the transmission of nociceptive stimuli to the central nervous system. It reduces postoperative pain sensitization and intensity. Currently, research on Anrikefon for preventive analgesia in LC patients is limited. It impacts on the recovery process is not yet fully understood. This study will compare drug administration before anesthesia induction with intra-operative administration.\n\nParticipants will be assigned to one of two groups with equal probability using computer-generated random numbers. Patients in the Preventive Analgesia group will receive Anrikefon injection 15 minutes before anesthesia induction. Bridging Analgesia group is the control group. Patients in this group will receive Anrikefon immediately after the gallbladder is detached from the liver. Both groups will receive the identical drug dosage of 1 μg\u002Fkg.\n\nBoth treatment groups will receive identical care beyond the time of Anrikefon administration. All patients will undergo standardized anesthesia management. Parecoxib sodium 40 mg will be injected for rescue analgesia if NRS score \\> 4. We will analyze the primary, secondary, and exploratory outcome measures after surgery, aiming to explore the optimal timing of Anrikefon and its impact on the patient's recovery process.",[409],"Postoperative Pain",[411,412,413,414,415],"Preventive Analgesia","Laparoscopic Cholecystectomy","Postoperative Acute Pain","Visceral Pain","Anrikefon","2026-06-29",{"date":368,"type":32},{"date":419,"type":32},"2026-06-02",{"date":421,"type":21},"2028-06-30",{"name":38,"class":39},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":22,"phases":433,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":116},"100508545","phase-1-safety-and-efficacy-of-autologous-insc-dap-in-the-treatment-of-parkinsons-disease-100508545","NCT05901818","Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease","Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease","Inclusion Criteria:\n\nAges between 30 and 85 years, males or females; Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria; Disease history over 3 years; Hoehn and Yahr Stage less than or equal to 4 during the medication \"on\" time; Responsive to levodopa treatment (Maximum rate of improvement in MDS-UPDRS, part 3, is over 30%).\n\nExclusion Criteria:\n\nAtypical Parkinsonian syndrome or secondary Parkinsonian syndrome; Accompanied with other central nervous system diseases; With other severe systemic diseases or dysfunction; With severe psychiatric disorders; Subjects are using hormone or cytotoxic drugs and cannot stop taking the drug during the trial; With cognitive disorders (MMSE\\\u003C24); With severe dyskinesia (MDS-UPDRS part 4, score in 4.1\u002F4.2 ≥ 2); Subjects have undergone previous brain surgery; Subjects are long-term user of anticoagulant; Subjects have intracranial lesions which may affect the surgery or follow-up studies as assessed by imaging; Subjects are unable to undergo MRI or AV133 PET examination; Pregnancy or in preparation for pregnancy; Not suitable to participate in this clinical trial as assessed by the study investigators\u002Fphysicians.","85 Years",{"count":432,"type":21},6,[434],"PHASE1","This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.",[437],"Parkinson's Disease",[439],"Autologous; iNSC; DA precursor cells; Parkinson's Disease; Cell therapy; Stereotaxic injection",{"date":368,"type":32},{"date":442,"type":32},"2021-04-01",{"date":444,"type":21},"2028-12-31",{"name":38,"class":39},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":212,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":454,"targetDuration":456,"studyType":164,"phases":4,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":468,"leadSponsor":469,"locationsCount":4},"100644160","cirp-and-cathepsin-b-in-neuroinflammation-after-intracerebral-hemorrhage-100644160","NCT07665255","CIRP and Cathepsin B in Neuroinflammation After Intracerebral Hemorrhage","A Prospective Observational Case-Control Study of Peripheral Blood CIRP, Cathepsin B, and Related Inflammatory Biomarkers in Patients With Intracerebral Hemorrhage","CIRP-ICH","Inclusion Criteria:\n\nIntracerebral hemorrhage group:\n\nAge 18 years or older Diagnosis of intracerebral hemorrhage confirmed by head CT or MRI Supratentorial hemorrhage No surgical treatment Hematoma volume less than 30 mL Admission within 24 hours after symptom onset The participant or the legally authorized representative\u002Fnext of kin is able to provide written informed consent\n\nHealthy control group:\n\nAge 18 years or older Recruited from the hospital health examination center No history of stroke, intracerebral hemorrhage, cerebral infarction, or other major neurological diseases No severe active infection, severe immune disease, hematologic disease, or end-stage severe heart, liver, or renal failure No acute infection, trauma, or other obvious stress state within the previous 2 weeks Able to provide written informed consent\n\nExclusion Criteria:\n\nIntracerebral hemorrhage group:\n\nTraumatic intracerebral hemorrhage Secondary intracerebral hemorrhage caused by brain tumor, cerebrovascular malformation, aneurysm, or hemorrhagic transformation of infarction Severe active infection, severe immune disease, or hematologic disease End-stage severe heart, liver, or renal failure Pregnant or lactating women Any other condition judged unsuitable by the investigator\n\nHealthy control group:\n\nHistory of stroke, intracranial hemorrhage, brain tumor, or other major neurological diseases Severe active infection, severe immune disease, or hematologic disease End-stage severe heart, liver, or renal failure Pregnant or lactating women Any other condition judged unsuitable by the investigator",{"count":455,"type":21},60,"1 Day","This is a single-center, investigator-initiated, prospective observational case-control study. Patients with intracerebral hemorrhage and healthy controls will be enrolled at Xuanwu Hospital, Capital Medical University. Peripheral venous blood samples will be collected for measurement of CIRP, Cathepsin B, and related inflammatory biomarkers. Clinical and imaging data will also be collected in the intracerebral hemorrhage group. The study aims to compare biomarker levels between patients with intracerebral hemorrhage and healthy controls and to explore the potential role of these biomarkers in neuroinflammation after intracerebral hemorrhage. No investigational treatment will be administered.",[130,459],"Nontraumatic Intracerebral Hemorrhage",[461,462,463],"Neuroinflammation","cirp","Cathepsin B","2026-06-22",{"date":466,"type":32},"2026-06-24",{"date":368,"type":21},{"date":444,"type":21},{"name":38,"class":39},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":18,"enrollmentInfo":477,"targetDuration":4,"studyType":22,"phases":479,"briefSummary":480,"conditions":481,"keywords":484,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":491,"leadSponsor":493,"locationsCount":40},"100635432","sivelestat-sodium-as-an-adjunct-to-endovascular-thrombectomy-for-acute-anterior-circulation-large-vessel-occlusion-100635432","NCT07552610","Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion","Efficacy and Safety of Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy in Acute Anterior Circulation Large-Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* 1.Symptoms and signs consistent with focal ischemia in the anterior circulation;\n* 2.Large vessel occlusion of the anterior circulation (internal carotid artery, M1\u002FM2 segment of the middle cerebral artery) confirmed by CTA\u002FMRA\u002FDSA;\n* 3.Undergoing mechanical thrombectomy;\n* 4.Age between 18-80 years, both male and female;\n* 5.Pre-stroke modified Rankin Scale (mRS) score ≤1;\n* 6.Time from symptom onset to thrombectomy ≤24 hours, including wake-up stroke or unwitnessed stroke; symptom onset is defined as the \"last known well\" (LKW);\n* 7.National Institutes of Health Stroke Scale (NIHSS) score ≥6 at admission;\n* 8.ASPECTS ≥3 for anterior circulation occlusion;\n* 9.Written informed consent provided by the patient or their legal representative.\n\nExclusion Criteria:\n\n* 1．Simultaneous acute occlusion of both the anterior and posterior circulation, or bilateral acute large-vessel occlusion in the anterior circulation;\n* 2．Failure to obtain a baseline NIHSS score before sedation or intubation by a neurologist or emergency physician;\n* 3．Seizure at stroke onset that precludes assessment of the baseline NIHSS score;\n* 4．Bilateral dilated pupils;\n* 5．Known allergy to sivelestat sodium or any of its excipients;\n* 6．Severe allergy or absolute contraindication to iodinated contrast agents;\n* 7．Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy;\n* 8．Blood glucose \\\u003C50 mg\u002FdL (2.8 mmol\u002FL) or \\>400 mg\u002FdL (22.2 mmol\u002FL);\n* 9．Platelet count \\\u003C50 \\* 10⁹\u002FL;\n* 10．Hereditary or acquired bleeding tendency, coagulation factor deficiency, current oral anticoagulant use with INR \\>1.7, or oral anticoagulant treatment within the previous 48 hours;\n* 11．Severe renal failure, defined as serum creatinine \\>3.0 mg\u002FdL (265.2 μmol\u002FL), glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin, or requirement for hemodialysis or peritoneal dialysis;\n* 12．Inability to complete the 90-day follow-up (e.g., no fixed residence or overseas patients);\n* 13．Suspected vasculitis or septic embolism;\n* 14．Suspected aortic dissection;\n* 15．Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, tumor, or arteriovenous malformation;\n* 16．Significant mass effect with midline shift;\n* 17．Evidence of internal carotid artery dissection causing flow limitation;\n* 18．Neurological disease or psychiatric disorder that may interfere with evaluation of the patient's condition;\n* 19．Pregnant or breastfeeding women;\n* 20．Confirmed rheumatic or autoimmune disease with long-term use of immunosuppressants or corticosteroids;\n* 21．Current treatment with chemotherapy or other immunomodulatory agents (e.g., recombinant human granulocyte colony-stimulating factor, Xuebijing, or ulinastatin);\n* 22．Participation in another clinical trial that may interfere with the results of this study;\n* 23．Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation or may pose a significant risk to the patient.",{"count":478,"type":21},868,[24],"Stroke remains a major global health burden, with acute ischemic stroke (AIS) accounting for more than 65% of all cases. Endovascular thrombectomy (EVT) has been established as a standard treatment for large vessel occlusion (LVO) stroke; however, \"futile recanalization\" remains common, with many patients failing to achieve favorable functional outcomes despite successful vessel reperfusion. Increasing evidence indicates that neutrophils and neutrophil extracellular traps (NETs) play important roles in post-reperfusion inflammation, thrombosis, and microcirculatory dysfunction, which may contribute to thrombolysis resistance and poor prognosis. Neutrophil elastase (NE), a key component associated with NETs, may further aggravate vascular injury and thrombus formation.\n\nSivelestat Sodium is a selective NE inhibitor that has demonstrated anti-inflammatory and organ-protective effects in patients with acute respiratory distress syndrome and in experimental models of cerebral ischemia. It may help preserve blood-brain barrier integrity, reduce brain edema, and improve neurological outcomes. Based on these findings, this study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sivelestat sodium as an adjunct to EVT in patients with acute anterior circulation large-vessel occlusive stroke within 24 hours of onset. The results of this study are expected to provide further clinical evidence for anti-inflammatory adjunctive treatment strategies aimed at reducing futile recanalization and improving functional outcomes in AIS.",[82,83,482,483],"Thrombectomy","Neutrophil Extracellular Trap Formation",[485,486,487],"Endovascular Thrombectomy","Sivelestat Sodium","Neutrophil elastase",{"date":489,"type":32},"2026-06-25",{"date":464,"type":32},{"date":492,"type":21},"2029-05-31",{"name":38,"class":39},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":18,"enrollmentInfo":502,"targetDuration":4,"studyType":22,"phases":503,"briefSummary":504,"conditions":505,"keywords":506,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":40},"100632850","phase-4-safety-and-efficacy-of-adjunctive-gm1-to-mechanical-thrombectomy-for-acute-anterior-circulation-large-vessel-occlusion-100632850","NCT07519044","Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion","Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study-IAT-GIANT (Ganglioside GM1 to Improve Outcomes in Anterior CirculatioN Thrombectomy)","IAT-GIANT","Inclusion Criteria:\n\n* 1.Age ≥18 years and ≤80 years\n* 2.Symptoms and signs consistent with anterior circulation ischemia;\n* 3.Computed tomography angiography (CTA) \u002Fmagnetic resonance angiography (MRA) \u002Fdigital subtraction angiography (DSA) confirmed occlusion of intracranial segment of internal carotid artery (ICA) or M1\u002FM2 segments of the middle cerebral artery (MCA M1\u002FM2);\n* 4.Acute ischemic stroke (AIS) selected for emergency endovascular treatment;\n* 5.Premorbid mRS ≤1;\n* 6.Time from symptom onset to randomization was within 24 hours, including patients with wake-up stroke or unwitnessed stroke; The time of symptom onset was defined as the Last Known Well (LKW);\n* 7.National Institutes of Health Stroke Score (NIHSS) ≥6 at admission;\n* 8.ASPECTS ≥3;\n* 9.Informed consent obtained from the patient or his\u002Fher legal representative.\n\nExclusion Criteria:\n\n* 1.Simultaneous acute occlusion of large vessels in both the anterior and posterior circulation or bilateral cerebral hemispheres.\n* 2.Baseline NIHSS is not obtained by a neurologist or emergency physician prior to sedation or intubation;\n* 3.Seizures at stroke onset which would preclude obtaining a baseline NIHSS;\n* 4.Bilateral dilated pupils;\n* 5.Allergy to GM1 or excipients;\n* 6.Severe contrast allergy or absolute contraindication to iodinated contrast;\n* 7.Systolic pressure \\>185 mmHg or diastolic pressure \\>110 mmHg, and cannot be controlled by antihypertensive drugs;\n* 8.Blood glucose \\\u003C50 mg\u002Fdl (2.8 mmol\u002FL) or \\>400 mg\u002Fdl (22.2 mmol\u002FL);\n* 9.Platelet \\\u003C50\\*10\\^9\u002FL;\n* 10.Known genetic or acquired bleeding diathesis, deficiency of anticoagulant factors, or oral anticoagulant drugs and INR \\> 1.7, or treated with direct oral anticoagulant agents in the prior 48 hours;\n* 11.Known Severe renal Failure as defined by a serum creatinine \\> 3.0 mg\u002Fdl (or 265.2 μmol\u002Fl) or glomerular filtration rate (GFR) \\\u003C30, or patient requires hemodialysis or peritoneal dialysis;\n* 12.Patients that cannot complete 90-day follow-up (e.g. no fixed residence, overseas patients, etc.);\n* 13.Presumed vasculitis or septic embolization;\n* 14.Suspicion of aortic dissection;\n* 15.Evidence indicates intracranial tumors (excluding small meningiomas), acute intracranial hemorrhage, tumors, or arteriovenous malformations (AVMs).\n* 16\\. Significant mass effect causing midline shift.\n* 17\\. The patient has neurological disease or mental disorder before onset, which affects the assessment of the condition;\n* 18.Females who are pregnant or in lactation;\n* 19.Hereditary glycolipid metabolic disorders (ganglioside storage diseases, such as familial amaurotic idiocy, retinal degenerative diseases);\n* 20.Autoimmune diseases, spine injuries, demyelinating diseases (e.g., Guillain-Barre syndrome)\n* 21.Participating in other clinical trials that could confound the evaluation of the study;\n* 22.Other circumstances that the investigator considers inappropriate for participation or may pose a significant risk to patients.",{"count":478,"type":21},[284],"Stroke is a leading cause of global mortality and morbidity, with acute ischemic stroke (AIS) accounting for approximately 65.3% of cases and resulting in roughly 3.4 million new cases annually in China. While endovascular thrombectomy (EVT) is the recommended first-line therapy for large vessel occlusion (LVO), achieving 80-90% recanalization, fewer than 50% of patients reach functional independence (mRS 0-2) due to \"futile recanalization\" caused by mechanisms like no-reflow and reperfusion injury. Monosialotetrahexosylganglioside (GM1) is a unique glycosphingolipid that crosses the blood-brain barrier to provide neuroprotection by suppressing oxidative stress, excitotoxicity, and apoptosis while promoting neurogenesis. Although Phase III trials like the FOCUS study confirmed GM1's safety and efficacy in AIS populations, its benefit specifically for patients undergoing mechanical thrombectomy remains unkown. Therefore, the IAT-GIANT study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of adjunctive GM1 in improving 90-day functional outcomes for AIS-LVO patients treated with EVT.",[217,82],[507,508,509],"GM1","Mechanical Thrombectomy","Acute Anterior Circulation Large Vessel Occlusion",{"date":466,"type":32},{"date":512,"type":32},"2026-05-14",{"date":514,"type":21},"2028-08-31",{"name":38,"class":39},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":535,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":116},"100644087","efficacy-and-safety-of-antihypertensive-treatment-with-mobile-stroke-units-in-ultra-early-intracerebral-hemorrhage-100644087","NCT07665827","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial","MSU-ICH","Inclusion Criteria:\n\n1. History and physical\u002Fneurological examination consistent with acute stroke.\n2. Age ≥18 years;\n3. Time from symptom onset to enrollment \\\u003C3 hours (onset defined as last known normal).\n4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg;\n5. Pre-stroke modified Rankin Scale (mRS) score ≤2;\n6. Informed consent obtained from the subject or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GCS) score ≤5.\n2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.\n3. Malignant disease or other serious primary illness with a life expectancy of \\\u003C3 months.\n4. Current participation in another interventional randomized clinical trial.",{"count":525,"type":21},706,[24],"MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.",[529,136,530,531,135,132,532,533,217,534],"Nervous System Diseases","Cardiovascular Diseases","Vascular Diseases","Cerebral Hemorrhage","Cerebral Hemorrhage, Hypertensive","Hemorrhagic Stroke, Intracerebral",[536,537,538],"intracerebral hemorrhage","mobile stroke units","Intensive blood pressure lowering","2026-06-18",{"date":466,"type":32},{"date":542,"type":21},"2026-06",{"date":544,"type":21},"2028-07",{"name":38,"class":39},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":280,"enrollmentInfo":553,"targetDuration":4,"studyType":22,"phases":555,"briefSummary":556,"conditions":557,"keywords":561,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":567,"completionDateStruct":568,"leadSponsor":570,"locationsCount":116},"100641226","phase-3-evaluating-bu-yang-huanwu-decoction-for-early-diabetic-vascular-disease-100641226","NCT07658807","Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease","Evidence-Based Evaluation and New Drug Translation Research of Early Intervention With the Classic Traditional Chinese Medicine Formula Bu Yang Huanwu Decoction for Preventing and Treating Diabetic Lower Extremity Vascular Disease","Inclusion Criteria:\n\n1. Aged 18 to 70 years (inclusive), male or female.\n2. Diagnosed with diabetes mellitus according to the Chinese Diabetes Society (2024) Guidelines.\n3. Glycated hemoglobin (HbA1c) \\\u003C 12%, with recent fasting blood glucose \\\u003C 7.0 mmol\u002FL OR postprandial blood glucose \\\u003C 10.0 mmol\u002FL, and triglycerides \\\u003C 1.7 mmol\u002FL.\n4. Diagnosed with LEAD, meeting the following criteria:\n\n   Rutherford Classification 2, 3, or 4.\n\n   Resting ABI ≤ 0.90, OR for patients with exertional symptoms and resting ABI \\> 0.90, a post-exercise treadmill test showing an ABI decrease of ≥15%.\n\n   Evidence of lower limb arterial stenosis or occlusion confirmed by duplex ultrasound, CTA, MRA, or DSA.\n5. TCM Pattern Diagnosis: Must conform to the TCM syndrome of Qi Deficiency and Blood Stasis, as defined by the study's TCM diagnostic criteria (referencing \"Practical Diagnostic Criteria for Blood Stasis Syndrome\" and \"Integrated Chinese and Western Medicine Peripheral Vascular Disease\"):\n\n   Main Symptom: Lower limb weakness, or feeling of heaviness\u002Fdiscomfort after prolonged walking.\n\n   Secondary Symptoms: Shortness of breath\u002Flassitude in speaking; dry mouth with desire to drink; scaly skin.\n\n   Tongue \\& Pulse: Tongue with teeth marks, pale-purple with petechiae\u002Fecchymosis; thin and choppy pulse.\n\n   (Diagnosis confirmed by meeting 1 main symptom OR 2 secondary symptoms, assessed by a qualified TCM practitioner.)\n6. Voluntarily signs the Informed Consent Form (ICF) and is willing and able to comply with all study procedures and visits.\n\nExclusion Criteria:\n\n1. Known bleeding disorders or history of intracranial hemorrhage.\n2. Current use of anticoagulants (e.g., warfarin, dabigatran, factor Xa inhibitors).\n3. Presence of active infection.\n4. Severe cardiac abnormalities on resting ECG (e.g., heart failure, ventricular tachycardia, ventricular fibrillation, multifocal ventricular contractions, prolonged corrected QT interval).\n5. History of acute coronary syndrome ≤ 12 months requiring dual antiplatelet therapy.\n6. Chronic liver disease (Child-Turcote-Pugh score ≥5) or chronic kidney disease stages 4-5 (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n7. History of malignancy (except cured basal cell carcinoma).\n8. Moderate to severe anemia, polycythemia vera, or any hyperviscosity syndrome.\n9. Planned lower limb revascularization or amputation.\n10. Concurrent or planned use of medicinal products containing Veratrum species.\n11. Pregnant or lactating women, or women of childbearing potential not using highly effective contraception.\n12. Known allergy or hypersensitivity to any component of the study medication (Qilong Capsules, aspirin).\n13. Patients with psychiatric disorders or judged to be uncooperative.\n14. Currently participating in another drug clinical trial or using therapies with similar purported effects.\n15. Any other condition deemed by the investigator to make the participant unsuitable for the trial.",{"count":554,"type":21},300,[79],"The goal of this clinical trial is to learn if adding a Traditional Chinese Medicine formula, Bu Yang Huanwu Decoction (specifically the capsule form called Hua Yu Wan Capsule), to standard treatment can help prevent leg pain at rest or foot ulcers in people with diabetic lower extremity vascular disease. The main questions it aims to answer are:\n\nDoes adding Hua Yu Wan Capsule to standard treatment lower the chance of developing leg pain at rest or foot ulcers after one year, compared to standard treatment alone?\n\nIs the treatment combination safe for participants?\n\nResearchers will compare two groups:\n\nGroup 1 (Experimental): Standard treatment (including aspirin, and medicines for blood sugar and cholesterol control) plus Hua Yu Wan Capsule.\n\nGroup 2 (Control): Standard treatment alone.\n\nParticipants in this study will:\n\nBe adults aged 18 to 70 years with diabetes and early to moderate lower extremity vascular disease (confirmed by tests like the Ankle-Brachial Index or ABI).\n\nBe randomly assigned to one of the two treatment groups.\n\nTake their assigned treatment for 6 months.\n\nAttend clinic visits at 1, 3 and 6 months during treatment, and again at 6 and 12 months after treatment ends for check-ups and tests.",[558,559,560],"Peripheral Arterial Disease","Diabetic Angiopathies","Arterial Occlusive Diseases",[558,562,563,564],"Ischemia","Medicine, Chinese Traditional","Randomized Controlled Trial","2026-06-15",{"date":464,"type":32},{"date":542,"type":21},{"date":569,"type":21},"2029-01",{"name":38,"class":39},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":579,"targetDuration":163,"studyType":164,"phases":4,"briefSummary":581,"conditions":582,"keywords":583,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":599,"locationsCount":116},"100642500","real-world-study-of-woven-endobridge-for-intracranial-aneurysm-treatment-100642500","NCT07620626","Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment","A Real-World Study of Intrasaccular Flow Disruption Devices for the Treatment of Intracranial Aneurysms","WEB-RWS","Inclusion Criteria:\n\nRetrospective Cohort:\n\n* Participants of any age and sex.\n* Patients treated for an intracranial aneurysm using a commercially available MicroVention Woven EndoBridge device.\n* Patients who completed at least one postoperative imaging follow-up.\n\nProspective Cohort:\n\n* Participants of any age and sex.\n* Patients treated for an intracranial aneurysm using a commercially available MicroVention Woven EndoBridge device.\n* The participant, or legally authorized representative if applicable, understands the study requirements and procedures and provides written informed consent before any study-specific data collection.\n\nExclusion Criteria:\n\nRetrospective Cohort:\n\n* Patients treated with a Woven EndoBridge device for whom intraoperative or postoperative follow-up imaging data are not available.\n* Patients considered by the investigator to be unsuitable for participation in this study.\n\nProspective Cohort:\n\n* Participants who are currently participating in, or plan to participate during the follow-up period, another clinical study that may affect the results of this study.\n* Patients who are currently unable or expected to be unable to complete follow-up.\n* Patients with a life expectancy of less than 1 year due to other diseases or conditions.\n* Patients considered by the investigator to be unsuitable for participation in this study.",{"count":580,"type":21},1000,"We designed the Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment (WEB-RWS), an ambidirectional, multicenter, post-market real-world study with a prospective active surveillance component. The study will include patients with IAs treated with commercially available WEB devices under the direction of treating physicians in routine clinical practice. Clinical, procedural, imaging, and safety data will be collected using a standardized electronic data capture system, with safety events adjudicated by an independent clinical events committee and imaging outcomes assessed by an independent core laboratory. The primary objective is to evaluate 12-month adequate aneurysm occlusion and major adverse events after WEB treatment. The study is expected to provide comprehensive post-market evidence on the real-world performance of the WEB device in China, including its safety, effectiveness, clinical appropriateness, and health economic value in routine neurointerventional practice.",[167],[584,585,586,172,167,587,588,589,590,591,592],"Woven EndoBridge","WEB Device","Intrasaccular Flow Disruption","Aneurysm Embolization","Real-World Study","Post-Market Study","Raymond-Roy Occlusion Classification","WEB Occlusion Scale","Active surveillance","2026-06-09",{"date":595,"type":32},"2026-06-11",{"date":597,"type":21},"2026-06-10",{"date":421,"type":21},{"name":38,"class":39},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":16,"minAge":607,"maxAge":608,"enrollmentInfo":609,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":116},"100515739","study-on-the-health-economic-burden-of-alzheimers-disease-in-china-100515739","NCT05995418","Study on the Health Economic Burden of Alzheimer's Disease in China","The Alzheimer's Disease Burden in China (ABC) Study: a Nationwide Multicentre Cross-sectional and Prospective Cohort Study","Diagnosed according to the National Institute on Aging-Alzheimer's 1.Association (NIA-AA) criteria for aMCI and AD.\n\n2.Clinical Dementia Rating (CDR) score greater than or equal to 0.5 3.Have good visual, auditory, and language functions, or can complete neuropsychological assessments after correction.\n\n4.Participants or their legal representatives sign informed consent. Exclusion criteria\n\n1. History of stroke with neurological focal signs and imaging findings consistent with cerebral small vessel disease (Modified Fazekas score ≥2).\n2. Presence of mental or neurological developmental delay.\n3. Presence of other known conditions that may cause cognitive impairment.\n4. Diagnosis of a disease that prevents completion of cognitive assessments.\n5. Refusal to sign informed consent at baseline.","40 Years","100 Years",{"count":610,"type":21},9510,"Alzheimer's disease (AD) presents a significant socio-economic challenge globally, with China experiencing a notable rise in its prevalence. This study addresses critical gaps in understanding AD's economic burden and quality of life (QoL) impacts on patients and caregivers in Mainland China.",[27],"2026-06-04",{"date":615,"type":32},"2026-06-05",{"date":617,"type":32},"2023-07-01",{"date":619,"type":21},"2027-01-01",{"name":38,"class":39},{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":629,"targetDuration":163,"studyType":164,"phases":4,"briefSummary":631,"conditions":632,"keywords":634,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":116},"100640833","multicenter-registry-study-of-patients-with-intracranial-dural-arteriovenous-fistulas-in-china-100640833","NCT07604688","Multicenter Registry Study of Patients With Intracranial Dural Arteriovenous Fistulas in China","Dural Arteriovenous Fistulas Registry, Evaluation, and Management Study in China (DREAM)","DREAM","Inclusion Criteria:\n\n* Patients diagnosed with intracranial dural arteriovenous fistula (IDAVF) or spinal dural arteriovenous fistula (SDAVF) by cerebral or spinal digital subtraction angiography (DSA)\n* Patients treated or evaluated at participating centers during the study period\n* Availability of complete clinical and imaging records, including baseline information, treatment records, and DSA images\n* For the prospective cohort, written informed consent signed by the patient or legal representative\n\nExclusion Criteria:\n\n* Patients with facial or scalp arteriovenous fistulas\n* Patients with non-dural vascular malformations or non-arteriovenous fistula vascular diseases, including cavernous malformations or venous malformations",{"count":630,"type":21},10050,"This multicenter registry study aims to clarify the incidence trends of intracranial dural arteriovenous fistulas (IDAVF) and spinal dural arteriovenous fistulas (SDAVF) in China, evaluate current treatment patterns, and establish a nationwide multicenter retrospective and prospective database. The study is designed as a multicenter retrospective and prospective observational study involving more than 60 core hospitals across seven major geographic regions of China. The retrospective phase will include patients diagnosed between February 28, 2015 and February 28, 2025, while the prospective phase will enroll patients from March 1, 2025 to March 1, 2030. Eligible participants are patients diagnosed with IDAVF or SDAVF by digital subtraction angiography (DSA). The study will analyze disease incidence and temporal trends, collect baseline demographic and clinical characteristics, and evaluate treatment outcomes including obliteration rate, recurrence rate, and clinical prognosis. The crude incidence rate per 100,000 person-years during the study period will also be calculated based on Chinese census population data. The primary endpoint is the improvement rate in modified Rankin Scale (mRS) score at 6 months after treatment. Secondary endpoints include obliteration and recurrence rates on imaging follow-up at 6 months and improvement in mRS score at 12 months after treatment. Statistical analyses will be performed using SAS 9.4 software, including descriptive analyses as well as univariate and multivariate regression analyses to identify factors associated with clinical outcomes and prognosis.",[633],"Intracranial Dural Arteriovenous Fistula",[635,636,637,638],"intracranial dural arteriovenous fistula","fistula","malforamtion","outcome",{"date":613,"type":32},{"date":641,"type":21},"2026-05-18",{"date":643,"type":21},"2030-02-28",{"name":38,"class":39},""]